Humoral IgG1 responses to tumor antigens underpin clinical outcomes in immune checkpoint blockade

A new Nature Medicine paper dissects how human IgG1 responses to tumour antigens underpin clinical outcomes in immune checkpoint blockade, highlighting a coordinated B-cell / T-cell axis in effective anti-tumour immunity